Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Lessened by Telos Capital Management Inc.

Telos Capital Management Inc. reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 47.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 51,594 shares of the medical research company’s stock after selling 47,300 shares during the quarter. Telos Capital Management Inc.’s holdings in Edwards Lifesciences were worth $3,820,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the last quarter. State Street Corp increased its holdings in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after acquiring an additional 256,538 shares during the period. Geode Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after acquiring an additional 284,918 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares during the period. Finally, Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $555,939,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW opened at $70.96 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a 50-day moving average of $72.49 and a two-hundred day moving average of $69.54. The stock has a market cap of $41.85 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 3.72 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a report on Thursday, January 16th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Citigroup increased their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Finally, Barclays raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $79.19.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,000 shares of company stock worth $547,430 over the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.